Form 4: ENDRA Life Sciences Director Lou Basenese Granted 5,384 Restricted Stock Units

ENDRA Life Sciences Inc. Director Lou Basenese was granted 5,384 restricted stock units (RSUs) on June 11, 2025, which will vest in full on June 11, 2026.

Summary

• Lou Basenese, a Director of ENDRA Life Sciences Inc. (NDRA), acquired 5,384 shares of Common Stock on June 11, 2025.
• The acquisition was in the form of restricted stock units (RSUs), which convert to common stock on a one-for-one basis.
• These RSUs were granted at a price of $0 per unit, indicating they are part of a compensation package.
• The 5,384 RSUs are scheduled to vest in full on June 11, 2026.
• Following this transaction, Lou Basenese directly beneficially owns a total of 5,385 shares of Common Stock.

Sentiment

Score: 6

Explanation: Slightly positive. The grant of RSUs to a director is a standard compensation practice that aligns the director's interests with shareholders, indicating continued engagement and a vested interest in the company's future performance. It is not a direct purchase, but still represents an increase in insider ownership.

Positives

• The grant of restricted stock units to a director aligns their interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The acquisition of shares by an insider, even as compensation, can signal confidence in the company's future prospects.

Future Outlook

The document does not provide forward-looking statements or guidance regarding the company's operational or financial performance, focusing solely on an insider transaction.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction, common across all industries for publicly traded companies. It reflects standard compensation practices for board members, aligning their incentives with shareholder value.

Related Party Transactions

• The acquisition of 5,384 restricted stock units by Director Lou Basenese represents a compensation grant from ENDRA Life Sciences Inc. to a related party (a director).

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with shareholder value, as the compensation's ultimate value depends on the company's stock price performance.
• Employees: While not directly impacting all employees, this type of equity compensation is a common practice for key personnel and directors, reflecting standard corporate governance.

Next Steps

• The 5,384 restricted stock units granted to Director Lou Basenese are expected to vest in full on June 11, 2026, at which point they will convert into common stock.

Key Dates

Keywords

ENDRA Life Sciences, NDRA, Form 4, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Stock Grant, Equity Compensation